Stem Cell Manufacturing Market Research Report - Forecast to 2027

Stem Cell Manufacturing Market: Information by Application (Therapy & Research & Cell), Product (Stem Cell Lines and Instruments, Consumables & Culture Media), End User (Pharmaceutical/Biotechnology Companies & CRO), & Region - Forecast till 2027

ID: MRFR/LS/5477-CR | April 2019 | Region: Global | 116 pages

Stem Cell Manufacturing Market Overview:

The stem cell manufacturing market is an upcoming and trending market where the stem cells are acquired from blood cells or part of bone marrow that have the properties to regenerate themselves into specialized cells in the human body and which are used for the development of various kinds of drugs and to see the chemical effect of drugs on various cells and tissues and to see the performance of these drugs whether they can repair or replace the damaged cells or tissues or not. 

The rising number of diseases and the increased research to find out curative drugs and preventive medicines for these diseases have increased the demand for stem cell manufacturing process and ultimately has led the stem cell manufacturing companies to increase expenditure and investments in terms of stem cell manufacturing process which has become necessary to meet the increasing demands. 

In addition to private players making investments in the stem cell manufacturing market, Governments in various countries have also made significant developments to increase the stem cell manufacturing volume and with improved technologies, this market has become a desirable market for every new player to enter. The stem cell manufacturing market is experiencing vast growth and is expected to reach a value of USD 17,469.6 Million by 2023 at a CAGR of around 17.5% with the North American region dominating the market.

COVID 19 Analysis:

The novel coronavirus or the Covid 19 pandemic has impacted most of the medical and healthcare market systems but the stem cell manufacturing market has not lost its significance as most of the companies and the bioprocessing industry has been indulged in the development of vaccines for the treatment of covid 19 and to focus on clinical trials in various countries. However, the operational and personnel management has remained a severe headache for the private companies in balancing staff onsite and working from home and to also meet the covid regulations and social distancing norms. 

The increased research in terms of clinical trials has proved to be effective in the treatment of the coronavirus with most importantly the clinical trials developed from MSC’s showing positive results and thus have been significantly used by various countries like the USA, France, Japan, Korea, Canada, etc. However, the nationwide lockdowns and denied wound care services have led to the decline in the stem cell therapy market and reduced the demand for stem cell manufacturing. Various companies have shown decreased sales due to restrictions in the supply of the products. It is expected that the post-lockdown period would be a great success for the stem cell manufacturing market revenue since people would now be more attracted towards mental peace and health. The application and the end-user segment are the key segments that are expected to drive market growth.



Stem cells play a vital role in the development and preparation of drugs that have been found suitable in the treatment of various diseases for which medical science had not even discovered about like the ongoing covid 19 virus. The key driver behind the rise of the stem cell manufacturing market has been that stem cells play an important role in disease management and research initiatives. The growing awareness about the use of stem cells in therapeutic treatments of various organ diseases has driven private players to invest more in the market and gain better results. 

The increased number of stem cell organizations have also boosted the market growth and the sudden increase in the use of stem cells in oncology for the treatment of cancer and tumors have generated a positive impact in the minds of the public at large towards the increased use of stem cell manufacturing process which has boosted the growth for stem cell manufacturing market. 


The major restraints in the stem cell manufacturing system have been the high costs associated with stem isolation, purification, and the manufacturing scale-up of stem lines is often indulged with high costs and technical difficulties which hinder the manufacturing process. 

Technology Analysis:

The stem cell manufacturing system has been based on technological advancements in itself and has emerged as a market due to rapid improvements in the technological aspect. The stem cell market research and developments have been based on the high-end technical systems involved in removing the stem cells from the parts of various tissues and parts of the bone marrow which in itself involves the usage of advanced systems in the form of peeling off stem cells and thus analyzing them. 

The continuous researches and innovations made in terms of developing drugs for the treatment of various diseases also involve the usage of various advanced technological systems. In addition, the companies are also focused on developing improved techniques for storing stem cells for longer use.

Study Objectives:

  • To analyze the trends that are prevalent in the global market regions and players that will dominate the global trends and lead the market operations towards growth figures that have been predicted by the prominent leaders in the international market and key experts for the ongoing forecast period that ends in 2028. 

  • To understand the scale of functioning of the global market segments that are prevalent through their ability to meet the vibrant needs of the target audience for market products and services in major mushrooming regions across the globe for the period. 

  • To draw a competitive scale amongst the global market players producing the electric commercial vehicles and to understand the recent developments of the key market players in the recent past that promise great results to the market for the ongoing forecast period and market trends that end in 2028. 

Segment Overview: 

The stem cell manufacturing system has been segmented as follows:

By Product

  • Consumables

  o Culture Media

  o Other Consumables

  • Instruments

  o Bioreactors and Incubators

  o Cell Sorters

  o Other Instruments

  • Stem Cell Lines

  o Hematopoietic stem cells (HSC)

  o Mesenchymal stem cells (MSC)

  o Induced Pluripotent Stem cells (iPSC)

  o Embryonic stem cells (ESC)

  o Neural Stem cells (NSC)

  o Multipotent adult progenitor stem cells

By Application

  • Research Applications

  o Life science research

  o Drug discovery and development

  • Clinical Application

  o Allogeneic stem cell therapy

  o Autologous stem cell therapy

  • Cell & Tissue Banking Applications

By End-User

  • Pharmaceutical & Biotechnology Companies

  • Hospitals & surgical centers

  • Cell & tissue banks

  • Other End Users 

By Region

  • North America

  • Europe

  • Asia-Pacific

  • Rest of the world 

Regional Analysis: 

The stem cell manufacturing market has been gaining importance and revenue from five different regions namely North America, South America, Europe, Asia Pacific, the Middle East, and Africa. The North American region holds the majority share and has been contributing significantly to the growth of the market in totality.

The major factors responsible for the dynamic growth of the stem cell manufacturing market in this region is a large number of imaging centers, ongoing research activities, technological developments in terms of advanced imaging systems, and the increased Government expenditure on data storage and collections have played a major role in increasing the medical image management market size. 

In addition to this Europe has also been making significant efforts towards the growth of the stem cell manufacturing market with revenues coming from France, Germany, and Italy commonly. Asia Pacific region is one of the significant rising regions due to a large proportion of population existing in such countries and the rising technological advancements and health expenditures have also boosted the demand for stem cell manufacturing process in these countries. 

Competitive Landscape: 

The competitive landscape in terms of the stem cell manufacturing market has been immense and nail-biting with new players easily entering the market and the existing players making huge investments in this segment. The big names from this market are:

  • Fujifilm (New York)

  • Becton, Dickinson, and Company(US)

  • Bio-Rad Laboratories, Inc(US)

  • Bristol-Myers Squibb Company(US)

  • Athersys, Inc(US)

  • Lonza (Switzerland)

  • Merck KGaA (Germany)

  • HiMedia Laboratories(India)

  • STEMCELL Technologies Inc.(US)

  • Thermo Fisher Scientific(US)

The key players in the market are more focused on developing future strategies and set themselves as joint ventures to increase the stem cell manufacturing market share and size. 

Recent Developments:

  • In August 2020, Cipla collaborated with the company Stempeutics and launched a new cell therapy for the treatment of critical limb ischemia. 

  • In March 2021, OrganaBio launched one of its greatest innovations in the stem cell manufacturing market, a hematopoietic stem cell that is useful in supporting allogeneic-based cell therapies. 

  • Recently stem cell banking segments have become more common in use which store stem cells developed from amniotic fluid for future use. These stem cells are stored in a stem cell bank of which the expenses are paid by the person and can be used by the person whenever he deems fit or for his blood relatives.

Report Overview: 

The Global report helps the investors to gain meaningful information about the market and make decisions wisely. The report discusses the steps taken by the market leaders to boost the market growth and inflate market valuation for their good. The report fully summarises the ongoing market scenario in the stem cell manufacturing market which would help the intended audience to seek more information about the market. The objective of the report was to fully summarise the key players in the market and their role in boosting the stem cell manufacturing market value. The report also discusses the future growth prospects and the competitive landscape in the stem cell manufacturing industry and lays down the expected growth rate of the market along with the hindrances it might have to face.

Report Scope:
Report Attribute/Metric Details
  Market Size   USD 17,469.6 Million
  CAGR   17.5% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Application, Product, End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Fujifilm (New York), Becton, Dickinson and Company(US), Bio-Rad Laboratories, Inc(US), Bristol-Myers Squibb Company(US), Athersys, Inc(US), Lonza (Switzerland), Merck KGaA (Germany), HiMedia Laboratories(India), STEMCELL Technologies Inc.(US), and Thermo Fisher Scientific(US)
  Key Market Opportunities   Growing public-private investments and funding in stem cell-based research
  Key Market Drivers

  • Increasing use of stem cells to treat various diseases
  • Increasing number of stem cell organizations globally

  • Frequently Asked Questions (FAQ) :

    The Stem cell manufacturing market is expected to reach a valuation of USD 17.4 billion by 2023.

    The Stem Cell Manufacturing Market is expected to exhibit a strong 17.5% CAGR over the forecast period from 2020 to 2027.

    The growing awareness about the utility of stem cells in the healthcare sector is the major driver for the stem cell manufacturing market.

    The Americas accounts for the largest market share Stem cell manufacturing.

    Leading players in the stem cell manufacturing market include Fujifilm, Bristol-Myers Squibb, Becton Dickinson and Company, Bio-Rad, and Athersys, among others.